VOLITIONRX LTD (VNRX) Stock Price & Overview
NYSEARCA:VNRX • US9286611077
The current stock price of VNRX is 0.2 USD. Today VNRX is up by 0.1%. In the past month the price decreased by -20.85%. In the past year, price decreased by -64.36%.
VNRX Key Statistics
- Market Cap
- 27.504M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.23
- Dividend Yield
- N/A
VNRX Stock Performance
VNRX Stock Chart
VNRX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VNRX. When comparing the yearly performance of all stocks, VNRX is a bad performer in the overall market: 93.57% of all stocks are doing better.
VNRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VNRX. VNRX has a bad profitability rating. Also its financial health evaluation is rather negative.
VNRX Earnings
On November 13, 2025 VNRX reported an EPS of -0.05 and a revenue of 627.28K. The company missed EPS expectations (-11.41% surprise) and missed revenue expectations (-63.4% surprise).
VNRX Forecast & Estimates
11 analysts have analysed VNRX and the average price target is 2.24 USD. This implies a price increase of 1022% is expected in the next year compared to the current price of 0.2.
For the next year, analysts expect an EPS growth of 30.9% and a revenue growth 13.26% for VNRX
VNRX Groups
Sector & Classification
VNRX Financial Highlights
Over the last trailing twelve months VNRX reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 36.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -267.93% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VNRX Ownership
VNRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 28.73 | 56.331B | ||
| COO | COOPER COS INC/THE | 14.88 | 14.518B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.73 | 12.077B | ||
| SOLV | SOLVENTUM CORP | 10.29 | 11.728B | ||
| LNTH | LANTHEUS HOLDINGS INC | 15.41 | 5.377B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 16.82 | 4.143B | ||
| ICUI | ICU MEDICAL INC | 16 | 3.269B | ||
| HAE | HAEMONETICS CORP/MASS | 11.69 | 2.921B | ||
| XRAY | DENTSPLY SIRONA INC | 8.65 | 2.533B | ||
| NEOG | NEOGEN CORP | 28.45 | 2.099B | ||
| UFPT | UFP TECHNOLOGIES INC | 21.08 | 1.657B | ||
| STAA | STAAR SURGICAL CO | 121.9 | 857.02M | ||
| BVS | BIOVENTUS INC - A | 11.34 | 733.254M |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VNRX
Company Profile
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Company Info
IPO: 2015-02-06
VOLITIONRX LTD
1489 West Warm Springs Road, Suite 110
Henderson NEVADA 78738 US
CEO: Cameron Reynolds
Employees: 85
Phone: 17024251561
VOLITIONRX LTD / VNRX FAQ
What does VOLITIONRX LTD do?
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
What is the stock price of VOLITIONRX LTD today?
The current stock price of VNRX is 0.2 USD. The price increased by 0.1% in the last trading session.
What is the dividend status of VOLITIONRX LTD?
VNRX does not pay a dividend.
What is the ChartMill rating of VOLITIONRX LTD stock?
VNRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does VOLITIONRX LTD belong to?
VOLITIONRX LTD (VNRX) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the Price/Earnings (PE) ratio of VOLITIONRX LTD (VNRX)?
VOLITIONRX LTD (VNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
What is the Short Interest ratio of VOLITIONRX LTD (VNRX) stock?
The outstanding short interest for VOLITIONRX LTD (VNRX) is 2.27% of its float.